Amryt Pharma
FDA turns down Amryt’s epidermolysis bullosa drug
Phil Taylor
Amryt Pharma, dermatology, epidermolysis bullosa, inherited disease, rare disease, regulatory
0 Comment
X
FDA turns down Amryt’s epidermolysis bullosa drug
https://pharmaphorum.com/news/fda-turns-down-amryts-epidermolysis-bullosa-drug/
X
Amryt to expand rare disease portfolio with $311m Aegerion merger
https://pharmaphorum.com/news/amryt-to-expand-rare-disease-portfolio-with-311m-aegerion-merger/
News/ News/ Patients/ UK & Europe
Amryt looking to expand rare disease franchise
Andrew McConaghie
Amryt Pharma, Rare diseases
0 Comment
Amryt looking to expand rare disease franchise
X
Amryt looking to expand rare disease franchise
https://pharmaphorum.com/news/amryt-looking-expand-rare-disease-franchise/